Latest Projects

banner

Activated Dendritic Cell Marker CD83

Dendritic cells (DCs) play a critical role in the generation and regulation of immune responses.  In the healthy individual these responses are directed towards pathogenic organisms and viruses, preventing or resolving infection.  Unfortunately DCs have been shown to play a major role in the development of autoimmune disease, transplanted organ rejection and graft versus host disease.  Non-specific removal of DCs to treat such conditions can lead to immunocompromisation and expose the patient to potentially life-threatening commensal infections.  Selective removal of ‘activated’ DCs has been shown to reduce inappropriate immune responses while preserving ‘non-activated’ DCs for subsequent anti-pathogen activity.
CD83 is a surface marker present on activated DCs.  Targeting CD83 as a mechanism for eliminating activated DCs has been shown to be effective in pre-clinical models of graft versus host disease, a often fatal adverse event associated with allogeneic haematopoietic stem cell transplantation (HSCT).

Anti-CD83 Antibodies Selectively Destroy Activated DCs

TransBio has created monoclonal antibodies to CD83 which cause activated DC destruction by antibody-dependent cell-mediated cytotoxicity (ADCC).  These include a number of fully human antibodies one of which is highly expressed in CHO cells and currently in production development at the Australian Institute of Biotechnology and Nanotechnology.  The lead reagent has been assessed in several in vitro and in vivo assays and is effective in the prevention of GVHD in an established animal model of the disease.  The CD83 strategy has the potential to treat other conditions including solid organ rejection and autoimmune disease.
Advantages of Targeting CD83
  • Used prophylactically with HSCT avoids onset of GVHD and its sequelae.  
  • Does not suppress immune system leaving graft versus leukaemia and antiviral responses unaffected.
TransBio is seeking to enter into discussions with parties interested in collaborative research programs, partnering and/or licensing.

Patent Application

  • US provisional 61/75980, filed 1st February 2013.

Published Articles

  • Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity. Munster DJ, et al. Int Immunol 16(1):33-42, 2004.
  • Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. Wilson J, et al. J Exp Med. 206(2):387-98, 2009.
This project was supported through Therapeutic Innovation Australia’s “Researcher Partnership Program”